Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Body mass index as a prognostic feature in operable breast cancer: The International Breast Cancer Study Group experience
Annals of Oncology, Volume 15, No. 6, Year 2004
Notification
URL copied to clipboard!
Description
Background: Current information on the prognostic importance of body mass index (BMI) for patients with early breast cancer is based on a variety of equivocal reports. Few have data on BMI in relationship to systemic treatment. Patients and methods: Patients (6792) were randomized to International Breast Cancer Study Group trials from 1978 to 1993, studying chemotherapy and endocrine therapy. BMI was evaluated with eight other factors: menopausal status, nodal status, estrogen receptor status, progesterone receptor status, tumor size, vessel invasion, tumor grade and treatment. BMI was categorized as normal (≤24.9), intermediate (25.0-29.9) or obese (≥30.0). Results: Patients with normal BMI had significantly longer overall survival (OS) and disease-free survival (DFS) than patients with intermediate or obese BMI in pairwise comparisons adjusted for other factors. Subset analyses showed the same effect in pre- and perimenopausal patients and in those receiving chemotherapy alone. When assessed globally and adjusted for other factors, BMI significantly influenced OS (P = 0.03) but not DFS (P = 0.12). Conclusions: BMI is an independent prognostic factor for OS in patients with breast cancer, especially among pre-/perimenopausal patients treated with chemotherapy without endocrine therapy. © 2004 European Society for Medical Oncology.
Authors & Co-Authors
Berclaz, Gilles
Switzerland, Bern
University Hospital Bern
Li, Sigui
United States, Boston
Dana-farber Cancer Institute
Price, Karen N.
United States, Boston
Dana-farber Cancer Institute
Coates, Alan S.
Australia, Sydney
The University of Sydney
Castiglione-Gertsch, Monica
Switzerland, Bern
Ibcsg Coordinating Center
Rudenstam, Carl Magnus
Sweden, Gothenburg
Sahlgrenska Universitetssjukhuset
Holmberg, Stig B.
Sweden, Gothenburg
Sahlgrenska Universitetssjukhuset
Lindtner, Jurij
Slovenia, Ljubljana
Onkološki Inštitut Ljubljana
Eržen, Darja
Slovenia, Ljubljana
Onkološki Inštitut Ljubljana
Collins, John Paxton
Australia, Melbourne
Royal Melbourne Hospital
Snyder, Raymond D.
Australia, Fitzroy
St. Vincent's Hospital Melbourne
Thürlimann, Beat J.K.
Switzerland, St Gallen
Kantonsspital St.gallen
Fey, Martin F.
Switzerland, Bern
University Hospital Bern
Mendiola, Caesar
Spain, Madrid
Madrid Breast Cancer Group
Werner, I. Dudley
South Africa, Observatory
Groote Schuur Hospital
Simoncini, Edda Lucia
Italy, Brescia
Spedali Civili Di Brescia
Crivellari, Diana
Italy, Aviano
Irccs Centro Di Riferimento Oncologico Aviano
Gelber, Richard D.
United States, Boston
Dana-farber Cancer Institute
Goldhirsch, Aaron
Switzerland, Bellinzona
Oncology Institute of Southern Switzerland
Italy, Milan
Istituto Europeo Di Oncologia
Statistics
Citations: 268
Authors: 19
Affiliations: 15
Identifiers
Doi:
10.1093/annonc/mdh222
ISSN:
09237534
Research Areas
Cancer